Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring

Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development.  They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or autoreactive cells. 

With the success of approved CAR-T cell therapies, designs have continued to evolve from first-generation CAR constructs with simplified designs to fifth-generation constructs that overcome challenges of prior generations (Zugasti, 2025; Moon, 2025). 

Tracking both the pharmacodynamic (PD) and the pharmacokinetic (PK) responses is critical in CAR therapy trials. Flow cytometry-based approaches that enable detailed evaluation of CAR-T persistence and phenotypic analysis are one such way to support the PK/PD biomarker strategy (Wang, 2025). 

Generating biologically relevant and actionable results from flow cytometry-based assays requires focused development and validation steps. KCAS Bio regularly supports the development and validation of flow cytometry methods for immunophenotyping and PK assays to track circulating CAR-T cells.  Considerations for method design include factors such as the intended use of data, sample matrix, sample stability, and critical endpoints.  While a variety of sample matrices can be used, PK methods conducted on fresh or fixed whole blood minimize sample manipulation, preserve biological endpoints, and allow reporting of absolute cell counts. A companion PD assay for use with either fresh whole blood or cryopreserved PBMCs can extend the exploration of a CAR-T study.      

Strategic Flow Cytometry Backbone Design for Rapid Pipeline Expansion

A well-designed assay not only generates reliable PK/PD for evaluating CAR persistence, phenotype, and biological activity but can also serve as a foundation for scaling future programs. 

As therapeutic pipelines expand, several technical and operational criteria can drive the transition from using a standalone PK/PD method to a broader backbone-based strategy:

  • Advancement to multi-asset clinical development
  • Need to support parallel PD and PK data generation
  • Time-sensitive initiation of clinical cohort testing
  • Planned future expansions into other clinical regions
  • Desire to maintain data continuity and cross-study comparability
  • Risk reduction through avoidance of full assay redevelopment

Operationalizing Continuity: Customization Without Re-development

As a trusted partner, KCAS Bio has helped sponsors leverage their investment in method development, reduce risk in sample analysis, and scale their global programs by using strategic customization of flow-cytometry methods. 

In a recent program, a sponsor leveraged a CAR-T PK method that we developed and qualified for their USA-based Phase I clinical trial.  KCAS Bio strategically customized this method to support the sponsor’s broader therapeutic pipeline. 

The starting 18-color method included more than 80 reportables per sample with reporting of frequency and absolute cell counts.  To prepare the method for a Phase II global study, evaluating a different CAR-T construct from the sponsor’s pipeline, we implemented strategic customization. Extensive re-development and re-qualification were avoided by preserving core assay components, workflows, and controls.  The optimized backbone method was retained, while CAR detecting antibodies were replaced with antibodies specific for detection of the alternative CAR-T construct. 

We carried out antibody titration, method optimization and re-qualification using fit-for-purpose test-scripts according to best practices (Monaghan, 2024) (Litwin, 2021). After re-qualification, the method was harmonized for use at our strategic alliance partner, CRUX Biolabs in Melbourne Australia.  Harmonization test-scripts evaluated precision across instruments, analysts and within the assay.  Acceptance criteria were met for all test-scripts, for every qualified reportable.  With harmonization completed, this spectral flow cytometry 18-color PK method is ready for use with whole blood clinical samples collected in the USA and APAC regions.

Through this approach, we enable faster clinical readiness and efficient global harmonization for a time-sensitive study; all without sacrificing data integrity.   Standard timelines for new method development, qualification, and global harmonization can span 4-6 months or longer, pending the complexity of the assay.  With this strategic customization approach, the total time from re-development to global clinical readiness was reduced by more than 50%.  

Using the knowledge established assay from the Phase I study, KCAS Bio efficiently worked through method optimization, qualification and harmonization, building critical efficiency for our sponsor’s time and budget.  Additionally, the established robustness of the Phase I assay reduces the potential risks associated with re-development efforts and enhances the likelihood of successful data analysis and interpretation for the global program.

Why Analytical Continuity Matters in Advanced Therapy Development

For clinical-stage cell therapy programs, the ability to evolve analytical strategies without disruption is critical. By establishing a robust PK foundation early and leveraging it strategically as the pipeline expanded, the sponsor avoided unnecessary redevelopment, preserved data continuity, and accelerated global clinical execution.

For sponsors developing complex modalities such as CAR-T therapies, working with a service provider capable of supporting method development, asset expansion, and global transfer through one team enables seamless progression, continuity, and ultimately, faster and more confident decisions. 

Want to learn more about KCAS Bio’s approach to strategic method development and customization?  Reach out today to connect.

References

Litwin, V. e. (2021). H62 Validation of Assays Performed by Flow Cytometry. USA: Clinical and Laboratory Standards Institute (CLSI).

Monaghan, S. E. (2024). Clinical Cytometry. Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines, 1-15.

Moon, S. S. (2025). CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from Clinical Trials.gov. Biomolecules & therapeutics , 33(6), 907–923. https://doi.org/10.4062/biomolther.2025.153.

Wang, W. L. (2025). Correaltion Between Chimeric Antigen Receptor T-Cell Pharmacokinetic Data Measured yb Flow Cytometry and Quantitative Polymerase Chain Reaction. Clinical and Translational Science. Zugasti, I. E.-A. (2025). CAR-T cell therapy for cancer: current challenges and future directions. . Signal Transduction and Targeted Therapy.